Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by DSM Capital Partners LLC

DSM Capital Partners LLC lessened its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 135,161 shares of the medical research company’s stock after selling 6,626 shares during the quarter. Thermo Fisher Scientific comprises about 1.1% of DSM Capital Partners LLC’s investment portfolio, making the stock its 24th biggest position. DSM Capital Partners LLC’s holdings in Thermo Fisher Scientific were worth $71,742,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of TMO. Cape Investment Advisory Inc. boosted its holdings in shares of Thermo Fisher Scientific by 52.0% during the fourth quarter. Cape Investment Advisory Inc. now owns 76 shares of the medical research company’s stock worth $40,000 after purchasing an additional 26 shares during the last quarter. Linscomb & Williams Inc. boosted its holdings in shares of Thermo Fisher Scientific by 0.9% during the fourth quarter. Linscomb & Williams Inc. now owns 3,125 shares of the medical research company’s stock worth $1,659,000 after purchasing an additional 28 shares during the last quarter. Founders Financial Alliance LLC boosted its holdings in shares of Thermo Fisher Scientific by 23.2% during the fourth quarter. Founders Financial Alliance LLC now owns 686 shares of the medical research company’s stock worth $364,000 after purchasing an additional 129 shares during the last quarter. Nixon Peabody Trust Co. boosted its holdings in shares of Thermo Fisher Scientific by 661.9% during the fourth quarter. Nixon Peabody Trust Co. now owns 31,542 shares of the medical research company’s stock worth $16,742,000 after purchasing an additional 27,402 shares during the last quarter. Finally, Sepio Capital LP boosted its holdings in shares of Thermo Fisher Scientific by 19.3% during the fourth quarter. Sepio Capital LP now owns 3,489 shares of the medical research company’s stock worth $1,852,000 after purchasing an additional 565 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Price Performance

NYSE:TMO traded down $0.98 during midday trading on Friday, hitting $584.05. 883,271 shares of the stock were exchanged, compared to its average volume of 1,282,267. Thermo Fisher Scientific Inc. has a one year low of $415.60 and a one year high of $603.82. The company has a market capitalization of $222.94 billion, a price-to-earnings ratio of 37.46, a P/E/G ratio of 2.73 and a beta of 0.80. The business has a 50-day moving average price of $576.44 and a two-hundred day moving average price of $547.49. The company has a current ratio of 1.70, a quick ratio of 1.33 and a debt-to-equity ratio of 0.68.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, April 24th. The medical research company reported $5.11 EPS for the quarter, topping the consensus estimate of $4.70 by $0.41. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. The firm had revenue of $10.35 billion for the quarter, compared to analysts’ expectations of $10.14 billion. Sell-side analysts predict that Thermo Fisher Scientific Inc. will post 21.65 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, July 15th. Shareholders of record on Friday, June 14th will be issued a $0.39 dividend. The ex-dividend date is Friday, June 14th. This represents a $1.56 annualized dividend and a dividend yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio is currently 10.01%.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $572.41, for a total value of $5,724,100.00. Following the transaction, the chief executive officer now owns 123,816 shares of the company’s stock, valued at $70,873,516.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $572.41, for a total transaction of $5,724,100.00. Following the transaction, the chief executive officer now directly owns 123,816 shares in the company, valued at approximately $70,873,516.56. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Michael A. Boxer sold 2,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, April 26th. The stock was sold at an average price of $567.94, for a total transaction of $1,135,880.00. Following the transaction, the senior vice president now owns 13,083 shares in the company, valued at $7,430,359.02. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 32,000 shares of company stock valued at $18,486,980. Corporate insiders own 0.34% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the company. Deutsche Bank Aktiengesellschaft increased their target price on Thermo Fisher Scientific from $600.00 to $610.00 and gave the stock a “buy” rating in a research report on Thursday, April 25th. Evercore ISI raised their price objective on Thermo Fisher Scientific from $575.00 to $610.00 and gave the company an “outperform” rating in a research report on Thursday, April 4th. The Goldman Sachs Group raised their price objective on Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a “buy” rating in a research report on Wednesday, April 10th. Barclays lifted their target price on Thermo Fisher Scientific from $590.00 to $615.00 and gave the stock an “equal weight” rating in a research report on Thursday, April 25th. Finally, Royal Bank of Canada lifted their target price on Thermo Fisher Scientific from $592.00 to $642.00 and gave the stock an “outperform” rating in a research report on Thursday, February 1st. Five analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat.com, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and an average target price of $605.31.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.